Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-885

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-885 Category Tag

Product Details

Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Proteoglycan 4 or lubricin is a surface-active mucinous glycoprotein secreted in the synovial joint that plays an important role in cartilage integrity. In healthy joints, lubricin molecules coat the cartilage surface, providing boundary lubrication and preventing cell and protein adhesion. Arthropathy occurring in patients with joint trauma, inflammatory arthritis or genetically mediated lubricin deficiencies have insufficient lubricin to prevent damage to articular cartilage. Ledelabricin Alfa is a human proteoglycan 4 isoform A variant, produced in Chinese hamster ovary (CHO) cells have been used to treat Arthropathy

Products Name (INN Index)

Pre-Made Ledelabricin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting PRG4(PROTEOGLYCAN 4)

INN Name

ledelabricin alfa

Target

PRG4(PROTEOGLYCAN 4)

Format

Recombinant Protein

Derivation

Human

Species Reactivity

Human

CH1 Isotype

PRG4 (lubricin, cartilage superficial zone proteoglycan, megakaryocyte stimulating factor) isoform A

VD LC

PRG4 (lubricin, cartilage superficial zone proteoglycan, megakaryocyte stimulating factor) isoform A

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Novartis?(Basel Switzerland)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

PRG4(PROTEOGLYCAN 4)

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide